Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin in hip fracture surgery
NCT00685958Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2006
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of enoxaparin in venous thromboembolism (VTE), sponsored by Sanofi. Primary endpoint: Bleeding events at 28 days. Started Jul 2006; status: completed.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00685958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00685958.